Robert J. Wechsler-Reya
Discovery Institute
CancerInternal medicineNeuroscienceChemistryImmunologySonic hedgehogCerebellumMedulloblastomaStem cellCell cycleCancer researchGeneticsCarcinogenesisSignal transductionComputational biologyMedicineBiologyHedgehog signaling pathwayImmune systemCell biology
Publications 191
#1Tannishtha ReyaH-Index: 39
view all 18 authors...
#1Jessica B. Foster (Children's Hospital of Philadelphia)H-Index: 7
#2Crystal Griffin (Children's Hospital of Philadelphia)
Last. Daniel Martinez (Children's Hospital of Philadelphia)H-Index: 27
view all 17 authors...
Pediatric brain tumors are the leading cause of cancer death in children with an urgent need for innovative therapies. Here we show that the neuroblastoma cell surface oncoprotein glypican 2 (GPC2) is also highly expressed on multiple lethal pediatric brain tumors, including medulloblastomas, embryonal tumors with multi-layered rosettes, other CNS embryonal tumors, as well as a subset of highly malignant gliomas including H3 G35 mutant gliomas and some H3 K28M diffuse midline gliomas. To target ...
#1Owen ChapmanH-Index: 1
Last. Ernest FraenkelH-Index: 50
view all 14 authors...
#1Bo-Rui Chen (DI: Discovery Institute)H-Index: 6
#2Anagha Deshpande (DI: Discovery Institute)H-Index: 3
Last. Aniruddha J. Deshpande (DI: Discovery Institute)H-Index: 21
view all 21 authors...
Leukemias bearing fusions of the AF10/MLLT10 gene are associated with poor prognosis, and therapies targeting these fusion proteins are lacking. To understand mechanisms underlying AF10 fusion-mediated leukemogenesis, we generated inducible mouse models of AML driven by the most common AF10 fusion proteins, PICALM/CALM-AF10 and KMT2A/MLL-AF10, and performed comprehensive characterization of the disease using transcriptomic, epigenomic, proteomic, and functional genomic approaches. Our studies pr...
#1Kent Riemondy (Anschutz Medical Campus)H-Index: 13
#2Sujatha Venkataraman (Anschutz Medical Campus)H-Index: 29
Last. Rajeev Vibhakar (Anschutz Medical Campus)H-Index: 30
view all 21 authors...
BACKGROUND Medulloblastoma (MB) is a heterogeneous disease in which neoplastic cells and associated immune cells contribute to disease progression. We aimed to determine the influence of neoplastic and immune cell diversity on MB biology in patient samples and animal models. METHODS To better characterize cellular heterogeneity in MB we used single-cell RNA sequencing, immunohistochemistry and deconvolution of transcriptomic data to profile neoplastic and immune populations in patient samples an...
1 CitationsSource
#1Runxiang Qiu (City of Hope National Medical Center)
#2Jun Wu (City of Hope National Medical Center)
Last. Qiang Lu (City of Hope National Medical Center)
view all 6 authors...
During mammalian brain development, neural progenitor cells proliferate extensively but can ensure the production of correct numbers of various types of mature cells by balancing symmetric proliferative versus asymmetric differentiative cell divisions. This process of cell fate determination may be harnessed for developing cancer therapy. Here, we test this idea by targeting KIF20A, a mitotic kinesin crucial for the control of cell division modes, in a genetic model of medulloblastoma (MB) and h...
#1Keisuke Katsushima (Johns Hopkins University)H-Index: 11
#1Keisuke Katsushima (Johns Hopkins University)H-Index: 1
Last. Ranjan J Perera (Johns Hopkins University)H-Index: 3
view all 18 authors...
BACKGROUND Medulloblastoma (MB) is an aggressive brain tumor that predominantly affects children. Recent high-throughput sequencing studies suggest that the noncoding RNA genome, in particular long noncoding RNAs (lncRNAs), contributes to MB subgrouping. Here we report the identification of a novel lncRNA, lnc-HLX-2-7, as a potential molecular marker and therapeutic target in Group 3 MBs. METHODS Publicly available RNA sequencing (RNA-seq) data from 175 MB patients were interrogated to identify ...
3 CitationsSource